Shoulder arthroplasty has become the established treatment for severe gleno-humeral disease from rheumatoid arthritis (RA) and osteoarthritis (OA), severe fracture, avascular necrosis (AVN), and cuff-tear arthropathy. Various implant designs have been developed over the past 20 years resulting in a large number of available implants. Clinical implant performance monitoring differs between countries. Registries are the best tools for long-term implant surveillance (Glicklich and Dreyer [@C7]). The first shoulder arthroplasty registry was created in Norway in 1994. Currently national shoulder arthroplasty registries exist in Norway, Sweden, Denmark, Australia, New Zealand, the United Kingdom (UK) (Rasmussen et al. [@C26]),and since 2014 in the Netherlands (Dutch Arthroplasty Register 2015). Recent reviews (Gonzalez et al. [@C8], Sanchez-Sotelo [@C28], Singh et al. [@C30], Zumstein et al. [@C35], Carter et al. [@C3], Smith et al. [@C32], Rasmussen [@C25], Pinkas et al. [@C24], Longo et al. [@C15]) and one health technology assessment report (Kärrholm et al. [@C13]) have highlighted the need for improved evidence in shoulder arthroplasty. Moreover, only a few national and international guidelines exist on the selection of the most appropriate procedure for the different indications (AAOS [@C1], NICE [@C17]).

Despite the recent growth in data collection (Rasmussen et al. [@C26]) there remains a dearth of epidemiological data on shoulder arthroplasty in different countries. Moreover, we are unaware of any publication presenting the annual incidence of shoulder arthroplasty in different countries. For this reason our aim was to examine the level of variation in indications, use of these procedures, and outcome reporting. Specific objectives were to (1) describe national incidence rates and trends; (2) examine trends in choice of type of procedure; (3) identify variation between different procedures and disease indications; (4) examine, where possible, variation in surgical volume; and (5) describe methods of outcomes assessment.

Materials and methods {#s0002}
=====================

All countries and regions having attempted to capture all shoulder arthroplasties were identified. Entry criteria for inclusion were: more than 2 years of publicly available data including recent years (\> 2010). We included publications from the following countries and/or national or regional registries: Australia, California (Kaiser Permanente Shoulder Arthroplasty Registry (Dillon et al. [@C5])), Denmark, Emilia-Romagna (North Italy), Germany, New Zealand, Norway, Sweden, and the UK. In all cases data were reported from registries except for Germany where data were based on publicly available hospitalization data from the Federal Bureau of Statistics in Wiesbaden, Germany (Oppermann et al. [@C19]). For simplicity the term registry will be used in the following for all countries/regions.

Analysis was focused on primary procedures, which are most frequent and more consistently documented. Data were extracted on the key variables "disease indication", "type of procedure", and "outcomes". The following disease indications were used: OA, cuff-tear arthropathy (as primary diagnosis), inflammatory arthritis, trauma (both acute trauma and trauma sequelae), and AVN. Procedures were categorized into the following implant sub-groups: total conventional arthroplasty, total reverse arthroplasty, hemi-arthroplasty, total resurfacing, and resurfacing hemi-arthroplasty. The reports from Germany and Norway included hemi-arthroplasty, total conventional and reverse arthroplasties without mention of resurfacing arthroplasty. For the key outcome, revision, information was extracted on how revision was defined and how the data were presented. In addition we recorded whether and how revision rates were recorded for different sub-groups. Finally, we examined the distribution of the number of procedures by surgeon, where these data were available.

Statistics {#s0003}
----------

Using population data from the Organisation for Economic Co-operation and Development (OECD) closest to the years in question, we calculated annual incidences of shoulder arthroplasty procedures per 100,000 inhabitants in the 7 countries included. The annual incidence trends were displayed graphically. Moreover, the highest and lowest incidence rate in 2012 were compared with use of an incidence rate ratio and its 95% confidence interval (CI), and the increase in annual incidence rate between 2002 and 2012 combining the 3 countries with available data (Norway, Sweden and New Zealand) was assessed with use of incidence rate difference and CI. Data were also extracted on mean ages at time of surgery, proportions of men and women, and distributions of indications for all years combined from the 9 registries. We calculated differences in proportions and their CIs for the comparison of the proportions of OA, cuff-tear arthropathy, and fracture in Sweden and New Zealand, the 2 registries with a similar time frame of data collection. Furthermore, variation in the proportion of different implant types used in the different countries/regions overall and in 3 different years (2000, 2006, and 2014 or closest years) was explored (data not readily available for California and Emilia-Romagna).

The distributions of type of procedure across disease indications were then calculated for each registry for the period including 2008 to the latest available year (exception California 2005--2013 and Denmark 2004--2012). The data by indication and type of procedure were cross-tabulated where available (not readily available for New Zealand). The level of difference between the registries for the 3 main disease--implant combinations was examined using meta-analysis methods. First, the proportion of total conventional arthroplasty in patients with OA was combined over registries using a model with random effects. A double arc-sine transformation (Miller [@C16]) was applied to proportions before combination and pooled estimates were obtained with the restricted maximum likelihood approach (Viechtbauer [@C33]). The between-registries variability was assessed by the I2 statistic: the I2 statistic ranges from 0% to 100% and values greater than 75% indicate a considerable heterogeneity between registries (Higgins et al. [@C10], Higgins and Green [@C9]). To capture the magnitude of this variability, the 95% prediction interval was also assessed. This interval shows the possible values of proportion of total conventional arthroplasty in patients with OA for a new registry (Higgins et al. [@C11]). Similar meta-analyses were conducted to combine the proportions of total reverse arthroplasty in patients with cuff-tear arthropathy and the proportions of hemi-arthroplasty in patients with fracture. Meta-analyses were conducted with package meta for R, Version 2.15.2 (R Foundation for statistical computing, Vienna, Austria).
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Results {#s0005}
=======

The numbers of shoulder arthroplasties in the 9 registries are shown in [Table 1](#TB1){ref-type="table"}. There was a female to male excess of between 1.5:1 and 2.5:1. On average, women were 5 to 7 years older than men at time of surgery. Registry data reporting started first in Norway in 1994. The annual incidence rates for the 7 countries with national data are shown in [Figure 1](#F0001){ref-type="fig"} and [Table 2](#TB2){ref-type="table"}. Their combined mean incidence rate in 2012 was 20 procedures/10^5^ population. In 2012, the variation between the incidence rate in the country with the highest (Germany: 34 procedures/10^5^ population) and the lowest incidence rate (UK: 5.6 procedures/10^5^ population) was 6-fold (CI 5.9--6.3). Between 2002 and 2012 annual incidence rates increased from 5 procedures/10^5^ population to 13 procedures/10^5^ population (rate difference 8, CI 7.6--8.8) in the 3 countries with available data (Norway, Sweden and New Zealand) (see [Figure 1](#F0001){ref-type="fig"}). An almost linear increase in procedure rates was seen in all registries with no evidence of levelling off.

![Annual incidence of shoulder arthroplasty procedures per 10^5^ inhabitants from 7 countries with a national registry.](iort-88-592.F01){#F0001}

###### 

Registries included

                                                   Years        Total number of   Women   Mean age                         
  ------------------------------------------------ ------------ ----------------- ------- ---------- ------ ---- ---- ---- -----------------------------------------
  Australia[^a^](#TF1){ref-type="table-fn"}        2007--2014   24,163            2,761   26,924     62%    73   69   71   Full country data collection since 2008
  California[^b^](#TF2){ref-type="table-fn"}       2005--2013   6,336                                56%              70   100% surgeon participation
  Denmark[^c^](#TF3){ref-type="table-fn"}          2004--2014   9,061                                70%    72   65   69   \> 90%
  Emilia-Romagna[^d^](#TF4){ref-type="table-fn"}   2008--2013   2,881             205     3,086      73%    73   65   71   97%
  Germany[^e^](#TF5){ref-type="table-fn"}          2008--2012   112,182                              74%                   100%
  New Zealand[^f^](#TF6){ref-type="table-fn"}      2000--2014   6,331             502     6,833      64%    72   68   71   \> 95%
  Norway[^g^](#TF7){ref-type="table-fn"}           1994--2014   5,621             536     6,157      73%              70   \> 90%
  Sweden[^h^](#TF8){ref-type="table-fn"}           1999--2013   11,414            10%                ≈65%             69   \> 80%
  United Kingdom[^i^](#TF9){ref-type="table-fn"}   2012--2014   11,399            1,291   12,755     72%    74   69   72   97%[^j^](#TF10){ref-type="table-fn"}

<https://aoanjrr.sahmri.com/documents/10180/217645/Shoulder%20Arthroplasty>. Not included 290 total mid-head and 21 hemi mid-head prostheses.

Dillon et al. 2015. Participation rate retrieved from Paxton et al. [@C23].

<https://www.sundhed.dk/content/cms/3/4703_dsr_%C3%A5rsrapport2015_final.pdf>

<https://ripo.cineca.it/pdf/relazione_2014_inglese_rev1.pdf>

Oppermann et al. 2016

<http://nzoa.org.nz/system/files/Web_DH7657_NZJR2014Report_v4_12Nov15.pdf>; coverage retrieved from <http://nzoa.org.nz/system/files/NZJR%2017%20year%20Report.pdf>

<https://www.kvalitetsregistre.no/sites/default/files/http-/nrlweb.ihelse.net/Rapporter/Rapport2015.pdf>

<http://ssas.se/files/docs/rapp14.pdf> and <https://www.ssar-rapport.se/SAAR_web/publicReport.html?category=skulder>

<http://www.hqip.org.uk/public/cms/253/625/24/95/2015-9-11%20NJR%20Online%20Annual%20Report%202015%20compressed.pdf?realName=Ey3Qcl.pdf>

Regarding the UK NJR, the compliance rate from April 1, 2014 to March 31, 2015 for hip and knee submissions was 97.0% for NHS hospitals in England and Wales. The data for the year April 1, 2015 to March 31, 2016 are not yet available (see <http://www.njrreports.org.uk/Data-Completeness-and-quality>). There are 5,400 primary shoulders being entered each year, and the compliance rate is expected to be high. Exact assessment of the compliance rate for shoulder arthroplasty submission is under way.

###### 

Incidence rates of shoulder prostheses in 2012 in the 7 countries with available national data

  Country/region   Population (millions)   Prostheses   Prostheses/ 10^5^ population
  ---------------- ----------------------- ------------ ------------------------------
  Australia        22.724                  3,587        16
  Denmark          5.592                   1,084        19
  Germany          80.426                  27,315       34
  New Zealand      4.433                   698          16
  Norway           5.019                   497          10
  Sweden           9.519                   1,227        13
  United Kingdom   58.405                  3,253        6

Between-registry differences in disease indication taking into account the entire time frame covered by the analysis were very large ([Table 3](#TB3){ref-type="table"}). OA was the most frequent indication in the English-speaking countries, in Germany and Emilia-Romagna, whereas the commonest cause in the Scandinavian countries was fracture. The proportion of arthroplasties performed for fracture varied substantially from 8% in the UK to more than 40% in Scandinavia. The proportion performed for inflammatory arthritis was highest in Norway, Sweden, and New Zealand, the 3 oldest registries. There was also a large variation in use of shoulder arthroplasty for cuff-tear arthropathy, which ranged from 2% in Norway to 20% in the UK. Taking into account only the two registries with a similar time frame covered by the analysis, Sweden and New Zealand, the differences remained (for OA 34% vs. 52% (difference 18%, CI 16--19); for cuff-tear arthropathy 7% vs. 19% (difference 11.8%, CI 11--13); for fracture 41% vs. 10% (difference 31%, CI 30--32)).

###### 

Distribution of indications by country/region. Values are number (%)

  Country/region                                    Osteoarthritis   Cuff tear arthropathy   Inflammatory arthritis   Acute fracture   Trauma sequelae   Avascular necrosis   Other       Total
  ------------------------------------------------- ---------------- ----------------------- ------------------------ ---------------- ----------------- -------------------- ----------- ------------------------------------------
  Australia                                         15,100 (63)      3,551 (15)              633 (3)                  3,920 (16)                         385 (2)              574 (2)     24,163
  California                                        3,790 (60)       949 (15)                89 (1)                   1,045 (17)       46 (1)            167 (3)              250 (3)     6,336
  Denmark                                           3,153 (32)       1,188 (12)              377 (4)                  4,207 (42)                         340 (3)              661 (7)     9,926
  Emilia-Romagna[^a^](#TF12){ref-type="table-fn"}   1,680 (59)       50 (2)                  32 (1)                   689 (24)         89 (3)            149 (5)              140 (5)     2,829
  Germany                                           60,738 (54)      3,194 (3)                                        38,422 (34)                                             9,825 (9)   112,182[^d^](#TF15){ref-type="table-fn"}
  New Zealand                                       3,402 (52)       1,255 (19)              570 (9)                  658 (10)         375 (6)           194 (3)              80 (1)      6,534
  Norway[^b^](#TF13){ref-type="table-fn"}           1,929 (33)       101 (2)                 910 (15)                 1,521 (26)       923 (16)                               543 (9)     5,927
  Sweden[^c^](#TF14){ref-type="table-fn"}           3,906 (34)       839 (7)                 1,242 (11)               4,700 (41)                         337 (3)              390 (3)     11,414
  United Kingdom                                    6,183 (54)       2,343 (21)              408 (4)                  877 (8)          492 (4)           201 (2)              199 (2)     11,399[^e^](#TF16){ref-type="table-fn"}

Differences in total numbers between this table and [Table 1](#TB1){ref-type="table"} and [4](#TB4){ref-type="table"} in Denmark, New Zealand and Norway are possibly due to 2 or more recorded diagnoses per procedure.

Information on indication for surgery was only available for 2,829 of the 2,881 procedures.

In Norway cuff-tear arthropathy is reported as "Other" with the option to specify the diagnosis. According to Rasmussen et al. [@C27] some cases may have been classified as "Osteoarthritis".

Source: <https://www.ssar-rapport.se/SAAR_web/publicReport.html?category=skulder>

Based on numbers provided in [Table 4](#TB4){ref-type="table"} of publication: Oppermann et al. [@C19].

Total additionally includes 696 (6.1%) procedures with 2 or more diagnoses.

Considering the whole registration period, proportions of different procedures ([Table 4](#TB4){ref-type="table"}) differed by country/region. Total reverse arthroplasty was most common in Emilia-Romagna, Australia, and the UK, hemi-arthroplasty in Scandinavia, and total conventional arthroplasty in New Zealand, California, and Germany. Because of differences in length of data collection and secular changes in procedure use we further assessed the proportions of total conventional and reverse arthroplasty as well as hemi-arthroplasty procedures at different points in time within a given registry and between the registries ([Figure 2](#F0002){ref-type="fig"}). Total conventional arthroplasty use, infrequent in 2000 and 2006, substantially increased in 2014 (or closest available year) in the Scandinavian countries. Between-registry differences ranged from 24% (2014) in Norway to 52% in Sweden (2013). The use of total reverse arthroplasty over the last 15 years in Norway and New Zealand increased from 12% to 52% and from 2% to 56%, respectively, whereas in Sweden its use remained stable (6--10%) over the examined period. Regarding hemi-arthroplasty use, in Australia "partial" replacement (defined in their annual report as a combination of partial resurfacing and hemi procedures) fell from 30% to 10% between 2008 and 2014. In Norway there was also a shift away from hemi-arthroplasty. For example (data not shown) from 2006 to 2012 there were on average 220 hemi-arthroplasties per year, whereas in 2013/14 this figure had dropped to 150/year. Within the most recent year the difference in use of hemi-arthroplasty was still substantial, with less than 10% in Australia and New Zealand, 22--25% in Germany, the UK, and Norway, and 37--41% in Denmark and Sweden.

![Distribution of the 3 main shoulder arthroplasty procedures performed by country for the years 2000, 2006, and 2014. 2000: Denmark data from 2004; Norway data for 1994--2005. 2006: Australia and Germany data from 2008. 2014: Germany data from 2012; Sweden data from 2013.](iort-88-592.F02){#F0002}

###### 

Distribution of types of procedures by country/region. Values are number (%)

  Country/region                            Total conventional arthroplasty   Hemi-arthroplasty   Resurfacing hemi-arthroplasty       Total resurfacing                   Total reverse arthroplasty   Total
  ----------------------------------------- --------------------------------- ------------------- ----------------------------------- ----------------------------------- ---------------------------- ------------------------------------------
  Australia                                 8,906 (37)                        4,048 (17)          1,346 (6)                           181 (1)                             9,682 (40)                   24,163
  California                                3,026 (48)                        2,79 (34)                                               191 (3)                             940 (15)                     6,336
  Denmark                                   1,017 (11)                        4,903 (54)          1,565 (17)                                                              1,313 (15)                   9,061[^b^](#TF18){ref-type="table-fn"}
  Emilia-Romagna                            253 (9)                           650 (23)                                                229 (8)                             1,697 (59)                   2,881
  Germany                                   50,661 (45)                       34,510 (31)                                                                                 27,011 (24)                  112,182[^c^](#TF19){ref-type="table-fn"}
  New Zealand                               2,409 (38)                        1,586 (25)          208 (3)                             118 (2)                             2,009 (32)                   6,331
  Norway                                    741 (13)                          3,316 (59)          [^d^](#TF20){ref-type="table-fn"}   [^d^](#TF20){ref-type="table-fn"}   1,564 (28)                   5,621
  Sweden[^a^](#TF17){ref-type="table-fn"}   3,561 (31)                        6,291 (54)                                              620 (5)                             942 (8)                      11,414
  United Kingdom                            3,350 (29)                        1,753 (15)          1,577 (14)                          592 (5)                             4,127 (36)                   11,399

Source: <https://www.ssar-rapport.se/SAAR_web/publicReport.html?category=skulder>

For Denmark type of procedure was not found for 263 (2.9%) cases in latest annual report.

Based on numbers provided in [Table 4](#TB4){ref-type="table"} of publication: Oppermann et al. [@C19].

For Norway use of resurfacing hemi-arthroplasty was described in 257 cases (2003--2014) in Rasmussen et al. [@C27]. No information on resurfacing in latest annual report.

The distribution of procedure by disease indication in most recent years (from 2008 on with the exception of California and Denmark) is shown in [Figure 3](#F0003){ref-type="fig"} for the registries with available data. To quantify how much the procedure sub-groups varied across registries we used meta-analysis techniques and evaluated the 3 most common disease--implant combinations. The combined proportion of total conventional arthroplasty in patients with OA was 45% (CI 35--55): for a typical registry, half of patients with OA had a total conventional arthroplasty ([Figure 4](#F0004){ref-type="fig"}). However, this proportion varied considerably across registries (I2 = 99.8%) and the observed variation cannot be explained by chance alone. If this proportion were calculated in a new registry, it would be expected to fall between 13% and 81% (prediction interval). When "Emilia-Romagna" and "Denmark" were removed from the meta-analysis, the combined proportion was 57% (CI 51--63), the heterogeneity between registries remained (I2 = 99.5%) and the prediction interval was still wide (34--78%). For total reverse arthroplasty in patients with cuff-tear arthropathy, the combined proportion was 77% (CI 60--91). Between-registry variability was considerable (I2 = 99.7%) and the prediction interval was from 13% to 100% ([Figure 5](#F0005){ref-type="fig"}). For hemi-arthroplasty in patients with fracture, the combined proportion was 68% (CI 54--80). Between-registry variability was considerable (I2 = 99.8%) and the prediction interval was from 19% to 89% ([Figure 6](#F0006){ref-type="fig"}).

![Distributions of implant choice across 5 disease indications by country/region.](iort-88-592.F03){#F0003}

![Forest plot illustrating between-registry variation in proportion of total conventional arthroplasty in patients with osteoarthritis.](iort-88-592.F04){#F0004}

![Forest plot illustrating between-registry variation in proportion of total reverse arthroplasty in patients with cuff tear arthropathy.](iort-88-592.F05){#F0005}

![Forest plot illustrating between-registry variation in proportion of hemi-arthroplasty in patients with fracture.](iort-88-592.F06){#F0006}

All registries evaluated "revision" as their key outcome. The definitions of revision are presented in Table 5 (see [Supplementary data](https://doi.org/10.1080/17453674.2017.1368884)). Most definitions included exchange or removal of a part or the whole and addition of a glenoid component. The degree of further details varied (e.g. how to account for a 2-stage revision). Regarding the ways of measuring and stratifying the results the registries used very different approaches (Table 6, see [Supplementary data](https://doi.org/10.1080/17453674.2017.1368884)). The Australian registry provides the most detailed analysis allowing the comparison of annual cumulative revision probabilities (with their 95% confidence intervals) for individual prosthesis brands, stratified by procedure type and disease indication among other factors.

Surgeon volume was indicated by 2 registries. The UK registry reported that a total of 553 consultant surgeons had carried out the primary replacements and the median number carried out in 2014 by each was 11 (IQR 2--31). In New Zealand 79 surgeons performed 801 shoulder procedures, an average of 10 procedures per surgeon in 2014. 

Discussion {#s0006}
==========

The widespread use of shoulder arthroplasty is more recent than that of hip and knee arthroplasty. Compared with the latter interventions, its incidence rate is about 10 and 7.5 times lower (Pabinger and Geissler [@C20], Pabinger et al. [@C21]), and the range of disease indications is wider (primary shoulder OA is uncommon). There is a weak evidence base as to which indication is the most appropriate for which procedure (Singh et al. [@C30], Kärrholm et al. [@C13], Villacis et al. [@C34]). A key source of such evidence in "real world" patients comes from population registries, and increasingly national and regional registries are collecting data on the indications for and the use and outcomes from the different approaches to shoulder arthroplasty (Rasmussen et al. [@C26]). There are also recent efforts to combine and compare data from different registries (Page et al. [@C22], Rasmussen et al. [@C27]). The existence of registry data from a number of countries around the world made it possible to provide for the first time the current status of shoulder arthroplasty. Our findings highlight unexplained/unmeasured variation in procedure choice that should prompt further research to aid evidenced-based decision-making in the use of these procedures. Moreover, it has also highlighted the need for harmonization of data analysis and outcomes presentation. Although all registries focus on revision as their key outcome, the way revision data are presented and the sub-groups into which the results are stratified differs largely. This variation thus limits international comparison of published results, which is important given the relatively low numbers with shoulder arthroplasty in an individual country, compared with hip and knee surgery.

The 9 registries whose data we analyzed varied in their length of data collection from over 20 years (Norway) to the UK's more recent 3 years. In all countries there was a strong upward trajectory in incidence at an almost parallel gradient, as also reported in the United States (Day et al. [@C4], Kim et al. [@C14], Schairer et al. [@C29]). It might suggest that for reasons including growing demand, increasing health care capacity, and/or expanding indications (Birkmeyer et al. [@C2], Villacis et al. [@C34]) countries could expect to see this continuation in growth.

We found large variation in main disease indications independent of length of data collection. This is likely partly due to the use of competing/alternative treatment methods (e.g. acute fracture treatment with osteosynthesis or non-operatively instead of joint replacement). There was also large variation in the use of the different procedures within the 3 main disease indications. This might be related to the lack of long-term data and guidelines for best practice. Moreover, issues related to training, level of capacity for this type of surgery, reimbursement habits, local availability of implants (approved in the country), and differences in marketing strategies towards surgeons/private hospitals/patients may also explain part of the variation (Birkmeyer et al. [@C2]). However, the latter factors as well as others (e.g. ease of surgery and patient recovery period) potentially influencing the surgeon's choice of procedure and implant brand are not documented in registries. Better knowledge of these issues will help optimize decision-making and improve patient outcomes.

The numbers of different manufacturers and models of implants was large (similar to hip and knee arthroplasty) and outside the scope of detailed analysis in this report. For example the UK registry quoted the use of 39 different brands of stems alone, excluding other brands for resurfacing. Individual registries frequently reported the use in single figures of a large number of available products. Given the smaller number of operations overall as compared with hip and knee arthroplasty and the wide variation in indications, it will be difficult or impossible to obtain sufficiently large samples for valid long-term effects' comparison. Limiting the available choice would help address this.

While it is unclear what is a reasonable annual number of such procedures for a surgeon to perform, data from the UK and New Zealand suggests that many surgeons are doing a low number annually. Increased postoperative complications and mortality as well as longer lengths of stay have been reported in the United States when shoulder arthroplasty was performed by low-volume surgeons and/or hospitals (Jain et al. [@C12], Singh et al. [@C31]). Finally, only a little information on patient characteristics prior to surgery was available in most registries. This lack of information on potentially confounding factors constitutes a major obstacle for the conduct of comparative effectiveness and safety studies.

Limitations {#s0007}
-----------

Analysis was restricted to the data published by the registries themselves. In none of the registries analyzed was it possible to calculate the age- or sex-specific population incidence for operation rates from the publicly available data. The reports varied in the consistency of the data used to calculate different subgroups, and the reasons for these inconsistencies were not always clear. In [Table 1](#TB1){ref-type="table"}, the number of primary procedures indicated represents the choice for which most subsequent information was available.

The diagnostic assignment may be subject to variation between and within countries. OA secondary to RA may be assigned to either disease. Similarly, the variation in the use of shoulder arthroplasty for cuff-tear arthropathy may be related to variation in the use of the classification (some registries coding cuff-tear arthropathy as OA, others, such as Norway, classifying it under "Other" with the possibility for special mention of cuff-tear arthropathy), changes in the use of diagnostic tests (e.g. MRI), as well as real surgical variation in this procedure.

There were also differences in how different procedures were described: for example the Australian registry stratified their interventions in different categories, separating all partial from all total arthroplasties. Furthermore, information on procedure choice by disease indication, when available, was not systematically reported for each individual year, thus limiting our ability to perform the between-registry comparison (see [Figure 3](#F0003){ref-type="fig"}) for the most recent year. However, to reduce the influence of the difference in length of data collection and of secular trends in procedure choice we restricted the analysis to the years 2008 onwards where possible.

Finally, coverage was high albeit not 100% in all registries. This is in accordance with a previous evaluation of the reported coverage of shoulder arthroplasty registries internationally (Rasmussen et al. [@C26]). There may be differences in reporting between elective and trauma care hospitals, which we are unable to verify because coverage according to categories of hospitals was not widely available. However, because of the high coverage in all the registries these differences, if present, are unlikely to substantially influence the study findings.

In summary, our findings highlight that despite the individual success for specific patients there is wide variation in use of shoulder arthroplasty at several levels with a lack of high-level evidence to alter this situation. The wide variety of available devices, often used in small numbers, is a cause for concern. There is also a need for harmonization of diagnoses, procedures, and outcomes. It is crucial to keep in mind that the conclusions reached in this review and meta-analysis are based on publicly available non-harmonized data with sometimes diverging definitions and classification systems. Nevertheless, the expanding creation of registries in this field of rapidly changing technology is encouraging. More needs to be done in improving our knowledge of benefits and harms of shoulder arthroplasty.

Supplementary data {#s0008}
------------------

Tables 5 and 6 are available in the online version of this article, <http://dx.doi.org/10.1080/17453674.2017.1368884>
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